Piper Sandler Sees 15%+ Growth at SharkNinja, Smith & Nephew Robotics Gains Surgeon Support
SN•Piper Sandler initiated SharkNinja with an Overweight rating and a $150 target, forecasting annual sales growth of at least 15% and EPS growth of 20% over three years. Surgeons at a London investor event endorsed Smith & Nephew’s CORI robotic-assisted surgery platform, enhancing confidence in its orthopaedics pipeline.
1. Piper Sandler Initiates SharkNinja Overweight Coverage
Piper Sandler initiated coverage of SharkNinja with an Overweight rating and set a $150 price target based on projected 2027 earnings. The firm forecasts at least 15% annual sales growth and 20% EPS growth over the next three years, citing a robust innovation pipeline and expanding advertising reach.
2. Emerging Growth Drivers for SharkNinja
Beyond category expansion and international markets, three key drivers support the bull case: direct-to-consumer sales expected to ramp after a consolidated website launch in late 2025; a margin-accretive Beauty category spanning hair and skin; and advertising spend that has more than doubled, fueling a 119% social media follower surge in 2025. A $750 million share repurchase authorization underscores healthy free cash flow.
3. Surgeons Back Smith & Nephew’s Robotic Platform
At a London investor event, surgeons provided positive feedback on Smith & Nephew’s CORI robotic-assisted surgery system, praising its precision and ergonomics. This endorsement bolsters confidence in the medical technology group’s orthopaedics pipeline and growth prospects for its surgical robotics platform.
